153 related articles for article (PubMed ID: 37100233)
1. SDH-B, INSM1, and GATA3 expression in cauda equina neuroendocrine tumors: report on 21 cases from a North indian tertiary care center.
Sood R; Chatterjee D; Bhardwaj S; Singla N; Ahuja C; Radotra B
Hum Pathol; 2023 Jul; 137():18-24. PubMed ID: 37100233
[TBL] [Abstract][Full Text] [Related]
2. Cauda Equina Neuroendocrine Tumors: Distinct Epithelial Neuroendocrine Neoplasms of Spinal Origin.
Asa SL; Mete O; Schüller U; Ramani B; Mirchia K; Perry A
Am J Surg Pathol; 2023 Apr; 47(4):469-475. PubMed ID: 36543154
[TBL] [Abstract][Full Text] [Related]
3. Cauda equina neuroendocrine tumors show biological features distinct from other paragangliomas and visceral neuroendocrine tumors.
Soukup J; Manethova M; Kohout A; Soukup T; Dvorakova R; Drugda J; Vitovcova B; Gabalec F; Kaiser M; Kanta M; Kasparova P; Kozak J; Michnova L; Netuka D; Reguli S; Rychly B; Trnkova M; Vachata P; Wozniakova M; Cesak T
Virchows Arch; 2023 Feb; 482(2):325-338. PubMed ID: 36348031
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical distinction of paragangliomas from epithelial neuroendocrine tumors-gangliocytic duodenal and cauda equina paragangliomas align with epithelial neuroendocrine tumors.
Mamilla D; Manukyan I; Fetsch PA; Pacak K; Miettinen M
Hum Pathol; 2020 Sep; 103():72-82. PubMed ID: 32668278
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity.
Schweizer L; Thierfelder F; Thomas C; Soschinski P; Suwala A; Stichel D; Wefers AK; Wessels L; Misch M; Kim HY; Jödicke R; Teichmann D; Kaul D; Kahn J; Bockmayr M; Hasselblatt M; Younsi A; Unterberg A; Knie B; Walter J; Al Safatli D; May SA; Jödicke A; Ntoulias G; Moskopp D; Vajkoczy P; Heppner FL; Capper D; Hartmann W; Hartmann C; von Deimling A; Reuss DE; Schöler A; Koch A
Acta Neuropathol; 2020 Dec; 140(6):893-906. PubMed ID: 32926213
[TBL] [Abstract][Full Text] [Related]
6. The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paraganglioma.
Ramani B; Gupta R; Wu J; Barreto J; Bollen AW; Tihan T; Mummaneni PV; Ames C; Clark A; Oberheim Bush NA; Butowski N; Phillips D; King BE; Bator SM; Treynor EC; Zherebitskiy V; Quinn PS; Walker JB; Pekmezci M; Sullivan DV; Hofmann JW; Sloan EA; M Chang S; Berger MS; Solomon DA; Perry A
Acta Neuropathol; 2020 Dec; 140(6):907-917. PubMed ID: 32892244
[TBL] [Abstract][Full Text] [Related]
7. Paraganglioma of the cauda equina: A clinicopathologic study of 12 cases with demonstration of cytokeratin positivity.
Zhang Y; Du Z; Xiong J; Wang Y; Yin B
Ann Diagn Pathol; 2022 Apr; 57():151887. PubMed ID: 35033938
[TBL] [Abstract][Full Text] [Related]
8. [Paraganglioma of the cauda equina region: Report of 9 cases].
Seidou F; Tamarit C; Sevestre H
Ann Pathol; 2020 Nov; 40(6):436-441. PubMed ID: 32331813
[TBL] [Abstract][Full Text] [Related]
9. Insulinoma-associated protein 1 immunostaining for various types of neuroendocrine tumors on FNA smears.
Hou T; Gan Q; Joseph CT; Sun X; Gong Y
Cancer Cytopathol; 2020 Oct; 128(10):725-732. PubMed ID: 32573984
[TBL] [Abstract][Full Text] [Related]
10. Comparison of INSM1 immunostaining with established neuroendocrine markers synaptophysin and chromogranin A in over 14,000 neuroendocrine and non-neuroendocrine tumors.
Möller K; Uhlig R; Gorbokon N; Dum D; Menz A; Büscheck F; Luebke AM; Hube-Magg C; Hinsch A; Höflmayer D; Fraune C; Lebok P; Weidemann S; Lennartz M; Jacobsen F; Clauditz TS; Steurer S; Burandt E; Krech R; Krech T; Marx AH; Sauter G; Simon R; Bernreuther C; Minner S
Mol Cell Endocrinol; 2024 Feb; 581():112106. PubMed ID: 37951531
[TBL] [Abstract][Full Text] [Related]
11. Insulinoma-associated protein 1 immunostaining on cytology specimens: an institutional experience.
Rodriguez EF; Fite JJ; Chowsilpa S; Maleki Z
Hum Pathol; 2019 Mar; 85():128-135. PubMed ID: 30502379
[TBL] [Abstract][Full Text] [Related]
12. Nuclear Insulinoma-Associated Protein 1 Expression as a Marker of Neuroendocrine Differentiation in Neoplasms of the Breast.
Seijnhaeve E; Galant C; Van Bockstal MR
Int J Surg Pathol; 2021 Aug; 29(5):496-502. PubMed ID: 33426999
[TBL] [Abstract][Full Text] [Related]
13. Primary Lumbar Paraganglioma: Clinical, Radiologic, Surgical, and Histopathologic Characteristics from a Case Series of 13 Patients.
Fiorini F; Lavrador JP; Vergani F; Bhangoo R; Gullan R; Reisz Z; Al-Sarraj S; Ashkan K
World Neurosurg; 2020 Oct; 142():e66-e72. PubMed ID: 32454200
[TBL] [Abstract][Full Text] [Related]
14. Cauda equina neuroendocrine tumor: a report of three cases and review of the literature with focus on differential diagnosis and postoperative management.
Fabbrocini L; Zin F; Keyvani K; Ebner FH
Neurosurg Rev; 2024 Apr; 47(1):166. PubMed ID: 38632184
[TBL] [Abstract][Full Text] [Related]
15. Well-differentiated rectal neuroendocrine tumors: analysis of histology, including insulinoma-associated protein 1 expression, and biologic behavior, involving a large cohort of 94 cases.
Sappenfield R; Gonzalez IA; Cao D; Chatterjee D
Hum Pathol; 2020 Oct; 104():66-72. PubMed ID: 32763255
[TBL] [Abstract][Full Text] [Related]
16. Locally invasive giant spinal paraganglioma.
Yi Chen B; Jose Mizrahi C; Yang Y; Kavar B
J Clin Neurosci; 2020 Aug; 78():430-432. PubMed ID: 32334958
[TBL] [Abstract][Full Text] [Related]
17. Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens.
Doxtader EE; Mukhopadhyay S
Cancer Cytopathol; 2018 Apr; 126(4):243-252. PubMed ID: 29360191
[TBL] [Abstract][Full Text] [Related]
18. Cauda equina neuroendocrine tumors: A single institutional imaging review of cases over two decades.
Ajmera P; Agarwal AK; Mehta PM; Benson JC; Madhavan AA; Diehn FE; Soni N; Bathla G
Neuroradiol J; 2024 Feb; 37(1):84-91. PubMed ID: 37933451
[TBL] [Abstract][Full Text] [Related]
19. Expression of novel neuroendocrine marker insulinoma-associated protein 1 (INSM1) in genitourinary high-grade neuroendocrine carcinomas: An immunohistochemical study with specificity analysis and comparison to chromogranin, synaptophysin, and CD56.
Chen JF; Yang C; Sun Y; Cao D
Pathol Res Pract; 2020 Jun; 216(6):152993. PubMed ID: 32381384
[TBL] [Abstract][Full Text] [Related]
20. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
